222 research outputs found
Disease Activity and Conversion into Multiple Sclerosis after Optic Neuritis Is Treated with Erythropoietin
No full textChanges in cerebral lesion load by magnetic resonance imaging (MRI) in patients from a double-blind, placebo-controlled, phase II study on erythropoietin in clinically isolated optic neuritis (ClinicalTrials.gov, NCT00355095) were analyzed. Therefore, patients with acute optic neuritis were assigned to receive either 33,000 IU of recombinant human erythropoietin (IV) daily for three days, or a placebo, as an add-on to methylprednisolone. Of 35 patients, we investigated changes in cerebral lesion load in MRIs obtained at baseline and at weeks 4, 8, and 16. In 5 of the 35 patients, we found conversion into multiple sclerosis (MS) based on MRI progression only. These five patients had received the placebo. Another five patients showed MRI progression together with relapses. Three of these patients had received erythropoietin, and two the placebo. Yet, analyzing the change in absolute numbers of periventricular, juxtacortical, and infratentorial lesions including gadolinium-enhancing lesions, there were no significant differences between the groups. Although effective in terms of retinal nerve fiber layer protection, erythropoietin treatment of acute isolated optic neuritis did not influence further evolution of MRI lesions in the brain when comparing absolute numbers. However, early conversion from clinically isolated syndrome to MS assessed by MRI activity seemed to occur more frequently in the placebo-treated group
New Cerebrospinal Fluid Research to Uncover Mechanisms Driving Neurological and Psychiatric Diseases
No full textThis eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contac
New Cerebrospinal Fluid Research to Uncover Mechanisms Driving Neurological and Psychiatric Diseases
No full textThis eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contac
sj-docx-2-tan-10.1177_17562864231211077 – Supplemental material for Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response
No full textSupplemental material, sj-docx-2-tan-10.1177_17562864231211077 for Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response by Valerie E. Teschner, Ann-Katrin Fleck, Carolin Walter, Anna-Sophie Schwarze, Melanie Eschborn, Timo Wirth, Olga V. Steinberg, Andreas Schulte-Mecklenbeck, I-Na Lu, Marisol Herrera-Rivero, Claudia Janoschka, Jan D. Lünemann, Nicholas Schwab, Gerd Meyer zu Hörste, Julian Varghese, Catharina C. Gross, Refik Pul, Christoph Kleinschnitz, Simone Mader, Edgar Meinl, Monika Stoll, Heinz Wiendl and Luisa Klotz in Therapeutic Advances in Neurological Disorders</p
sj-docx-3-tan-10.1177_17562864231211077 – Supplemental material for Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response
No full textSupplemental material, sj-docx-3-tan-10.1177_17562864231211077 for Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response by Valerie E. Teschner, Ann-Katrin Fleck, Carolin Walter, Anna-Sophie Schwarze, Melanie Eschborn, Timo Wirth, Olga V. Steinberg, Andreas Schulte-Mecklenbeck, I-Na Lu, Marisol Herrera-Rivero, Claudia Janoschka, Jan D. Lünemann, Nicholas Schwab, Gerd Meyer zu Hörste, Julian Varghese, Catharina C. Gross, Refik Pul, Christoph Kleinschnitz, Simone Mader, Edgar Meinl, Monika Stoll, Heinz Wiendl and Luisa Klotz in Therapeutic Advances in Neurological Disorders</p
sj-jpg-4-tan-10.1177_17562864231211077 – Supplemental material for Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response
No full textSupplemental material, sj-jpg-4-tan-10.1177_17562864231211077 for Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response by Valerie E. Teschner, Ann-Katrin Fleck, Carolin Walter, Anna-Sophie Schwarze, Melanie Eschborn, Timo Wirth, Olga V. Steinberg, Andreas Schulte-Mecklenbeck, I-Na Lu, Marisol Herrera-Rivero, Claudia Janoschka, Jan D. Lünemann, Nicholas Schwab, Gerd Meyer zu Hörste, Julian Varghese, Catharina C. Gross, Refik Pul, Christoph Kleinschnitz, Simone Mader, Edgar Meinl, Monika Stoll, Heinz Wiendl and Luisa Klotz in Therapeutic Advances in Neurological Disorders</p
sj-docx-1-tan-10.1177_17562864231211077 – Supplemental material for Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response
No full textSupplemental material, sj-docx-1-tan-10.1177_17562864231211077 for Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response by Valerie E. Teschner, Ann-Katrin Fleck, Carolin Walter, Anna-Sophie Schwarze, Melanie Eschborn, Timo Wirth, Olga V. Steinberg, Andreas Schulte-Mecklenbeck, I-Na Lu, Marisol Herrera-Rivero, Claudia Janoschka, Jan D. Lünemann, Nicholas Schwab, Gerd Meyer zu Hörste, Julian Varghese, Catharina C. Gross, Refik Pul, Christoph Kleinschnitz, Simone Mader, Edgar Meinl, Monika Stoll, Heinz Wiendl and Luisa Klotz in Therapeutic Advances in Neurological Disorders</p
- …
